Excision Biotherapeutics

Excision BioTherapeutics is a biotechnology startup that operates in the field of gene therapy. The company's primary focus is on developing a functional cure for HIV, a feat they have already achieved in animals. They use a revolutionary gene-editing technology called CRISPR, which they have licensed from the Doudna Lab at UC Berkeley and the Khalili Lab at Temple University.

CRISPR, which stands for Clustered Regularly Interspaced Short Palindromic Repeats, is a technology that allows scientists to edit genes within organisms. In simple terms, it's like a pair of molecular scissors that can cut out harmful genes and replace them with healthy ones. Excision BioTherapeutics uses this technology to target and remove the HIV genome from the body, thereby curing the disease.

The company's business model is based on the development and commercialization of its gene therapies. Once a therapy is developed, it can be sold to healthcare providers who administer it to patients. The company's primary market is individuals living with HIV, but the technology has the potential to be used to cure other infectious diseases as well.

Excision BioTherapeutics generates revenue by selling its gene therapies. The therapies require only a one-time edit to remove the viral genome permanently, which could make them a cost-effective solution for healthcare providers and patients.

In conclusion, Excision BioTherapeutics is a pioneering biotech startup that is using cutting-edge gene-editing technology to develop a functional cure for HIV. The company's innovative approach has the potential to revolutionize the treatment of infectious diseases and bring much-needed therapies to patients around the world.

Keywords: Excision BioTherapeutics, biotechnology, gene therapy, HIV cure, CRISPR, gene editing, Doudna Lab, Khalili Lab, infectious diseases, healthcare providers.